Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Thrombocytopenia 1Sarcoma 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Lymphopenia 1Cytopenia 1Chondrosarcoma 1Bone Neoplasms 1Anemia 1

Interventions

Epoetin Alfa 7Darbepoetin alfa 6epoetin beta 4Lenalidomide 4Cyclophosphamide 4ACE-011 4fludarabine 3Busulfan 3thymoglobulin 2telapristone acetate 2luspatercept 2fludarabine phosphate 2Cyclosporine 2Antilymphocyte Serum 2AP 1903 reagent 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2vactosertib 1ruxolitinib 1roxadustat 1obinutuzumab 1ibrutinib 1fosphenytoin 1ferrous sulfate 1ferric gluconate 1ferric carboxymaltose 1eltrombopag 1angiotensin I (1-7) 1Whole-Body Irradiation 1Thiotepa 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anemia × angiotensin I (1-7) × Clear all
NCT00771810 2017-11-13

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Tarix Pharmaceuticals

Phase 2 Completed
34 enrolled 19 charts
Classical hematologyGynecologic

Cytopenia, Anemia, Lymphopenia, Neutropenia, Ovarian Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡